Markets

Modest IPOs, Secondaries Follow Facebook Face Plant

By |

The last days of October saw a revival of emerging growth company initial and secondary public offering filings by financial companies ranging from commercial banks to REITS to hedge fund advisories. West Coast Realty Trust's latest regulatory filing describes plans for an IPO raising about $20.2 million for a retail property REIT operation. The company is starting off by acquiring two properties in California's Sacramento area. The company plans on buying properties in middle and high income regions in California, Northern Nevada and Hawaii. Affiliate University Capital Management will serve as property manager for these and other acquisitions.

Deals
BFAM

Bain Bringing Bright Horizons Private to Public

By |

Bain Capital is working with underwriters Goldman Sachs, Barclays Capital and JPMorgan Chase to orchestrate an initial public offering for child care provider Bright Horizons Family Solutions, a company Bain took private some four years ago. The new issue will trade under the ticker BFAM. The deal initially emerged as a shadowy one earlier this month, when Reuters heard of it from unnamed sources, but now a regulatory filing confirms the IPO plans. Bright Horizons traded on Nasdaq from 1998 into May 2008, when Bain funds took it private in a deal valued at $1.3 billion. The company hopes to raise as much as $220 million in an offering where Bain will retain significant influence, the filing says.

Markets
Biotech

IPOs Looking Good to Biotechs

By |

Share prices of Kythera Biopharmaceuticals (KYTH) and Intercept Pharmaceuticals(ICPT) popped significantly Thursday following their initial public offerings, indicating an appetite for fresh biotech issues. Calabasas, Calif.-based Kythera, which sold 4.4 million shares for $16 each to raise $70.4 million, opened at $18.49 a share and ended the day at $19.79 a share. New York-based Intercept sold 5 million shares at $15 each to raise $75 million. It opened at $19.40 a share and closed its first day at $19.40 a share. In both cases, the issuers upsized the number of shares offered and priced at the high end of their respective ranges.

Deals

Regulus Therapeutics Dual Tracks PIPE, IPO

By |

MicroRNA therapeutics developer Regulus Therapeutics (RGLS) announced that it has raised $25 million in a Common Stock transaction with investor AstraZeneca AB. The common stock was sold at $4.00 per share, an approximate 5% discount to the market price ($4.20) of RGLS at deal announcement.. The transaction closed on Oct. 10, 2012. This Placement was conducted concurrently with the Company's Initial Public Offering.